Ye Xu

Ye Xu

Auto-generated profile, based on publicly available information

Ye Xu

School of Basic Medical Sciences, Jilin Medical University, Jilin, 132013, China

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2012 in Cancer Letters
Verified
Journal Article
Closed access
YXYe Xu
Ye Xu
HYHuimei Yu
Huimei Yu
HQHanjiao Qin
Hanjiao Qin
JKJinSong Kang
JinSong Kang
CYChunyan Yu
Chunyan Yu
LSLianKun Sun
LianKun Sun

28 September 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
LQLing Qi
Ling Qi
HYHongquan Yu
Hongquan Yu
YZYu Zhang
Yu Zhang
DZDonghai Zhao
Donghai Zhao
PLPeng Lv
Peng Lv
YXYe Xu
Ye Xu
IL-10 secreted by M2 macrophage promoted tumorigenesis through interaction with JAK2 in glioma

1 July 2011 in European Journal of Cancer
Verified
Journal Article
Closed access
HYHuimei Yu
Huimei Yu
JSJing Su
Jing Su
YXYe Xu
Ye Xu
JKJinsong Kang
Jinsong Kang
HLHongyan Li
Hongyan Li
LSLiankun Sun
Liankun Sun

24 September 2014 in International Journal of Oncology
Verified
Journal Article
Closed access
MXMeihui Xia
Meihui Xia
HYHuimei Yu
Huimei Yu
SGShuang Gu
Shuang Gu
YXYe Xu
Ye Xu
JSJing Su
Jing Su
MCManhua Cui
Manhua Cui
Spandidos Publications is a scientific publisher with a long-standing international reputation for excellent standards and high quality science publications

1 February 2016 in Neurobiology of Aging
Verified
Journal Article
Closed access
CWChun-Yan Wang
Chun-Yan Wang
ZWZhan-You Wang
Zhan-You Wang
JXJing-Wei Xie
Jing-Wei Xie
TWTao Wang
Tao Wang
XWXu Wang
Xu Wang
JCJian-Hui Cai
Jian-Hui Cai

7 April 2022 in Cell Death & Disease
Verified
Journal Article
Open access
PDF file
WYWang Yi-Bin
Wang Yi-Bin
LXLi Xiang
Li Xiang
YBYang Bing
Yang Bing
ZQZhang Qi
Zhang Qi
JFJiao Fei-Tong
Jiao Fei-Tong
WCWang Chun-Yan
Wang Chun-Yan
Neuroinflammation occurs early in Alzheimer’s disease (AD). The initial stage of AD is related to glial dysfunction, which contributes to impairment of Aβ clearance and disruption of synaptic connection. CEBPβ, a member of the CCAAT-enhancer-binding protein (CEBP) family, modulates the expression of inflammation-associated genes, and its expression is elevated in brains undergoing degeneration and injured brains. However, the mechanism underlying CEBPβ-mediated chronic inflammation in AD is unclear. In this study, we observed that increases in the levels of nuclear CEBPβ facilitated the interaction of CEBPβ with the NFκB p65 subunit, increasing the transcription of proinflammatory cytokines in the APP/PS1 mouse brain. Oral administration of nanocarrier-packaged carnosic acid (CA) reduced the aberrant activation of microglia and astrocytes and diminished mature IL-1β, TNFα and IL-6 production in the APP/PS1 mouse brain. CA administration reduced β-amyloid (Aβ) deposition and ameliorated cognitive impairment in APP/PS1 mice. We observed that CA blocked the interaction of CEBPβ with NFκB p65, and chromatin immunoprecipitation revealed that CA reduced the transcription of the NFκB target genes TNFα and IL-6. We confirmed that CA alleviated inflammatory mediator-induced neuronal degeneration and reduced Aβ secretion by inhibiting the CEBPβ-NFκB signalling pathway in vitro. Sulfobutyl ether-beta-cyclodextrin (SBEβCD) was used as the encapsulation agent for the CA-loaded nanocarrier to overcome the poor water solubility and enhance the brain bioavailability of CA. The CA nanoparticles (NPs) had no obvious toxicity. We demonstrated a feasible SBEβCD-based nanodelivery system targeting the brain. Our data provide experimental evidence that CA-loaded NPs are potential therapeutic agents for AD treatment.